ACVRL1 and hereditary hemorrhagic telangiectasia: However, the fact remains that for HHT patients, already carrying an inherited mutation that reduces BMP9/10 signaling, the most likely molecular mechanism for further reduction in this signaling pathway is inactivation of the remaining wild-type copy of the HHT gene through somatic mutation.